Stay updated on IMP321 with Paclitaxel in Metastatic Breast Carcinoma Clinical Trial
Sign up to get notified when there's something new on the IMP321 with Paclitaxel in Metastatic Breast Carcinoma Clinical Trial page.

Latest updates to the IMP321 with Paclitaxel in Metastatic Breast Carcinoma Clinical Trial page
- CheckyesterdayChange DetectedThe page history shows a new revision label 'Revision: v3.3.3' was added, and the 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' text were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe Record History shows a revision update from v3.2.0 to v3.3.2. No study data, eligibility, outcomes, or navigation were altered.SummaryDifference0.1%

- Check30 days agoChange DetectedRemoved the government funding operating-status notice that previously informed users about potential delays and NIH Clinical Center operations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check52 days agoChange DetectedThe old and new screenshots show the same study page with only visual/layout differences; no changes to study status, eligibility, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check73 days agoChange DetectedThe page has been updated to v3.2.0 and adds a government-operational status notice, while removing the previous v3.1.0 reference.SummaryDifference10%

- Check81 days agoChange DetectedUpdated the page from Revision: v3.0.2 to Revision: v3.1.0, signaling a new software version.SummaryDifference0.2%

Stay in the know with updates to IMP321 with Paclitaxel in Metastatic Breast Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IMP321 with Paclitaxel in Metastatic Breast Carcinoma Clinical Trial page.